Cardiovascular health is one of the most important markers of long-term wellbeing. Against that backdrop, the supplement market has flooded with products making sweeping claims — claims that frequently outpace the evidence by a considerable margin.
This guide does not sell optimism. It works through the mechanisms, the trial data, and the honest limitations of the nutrients most relevant to cardiovascular function: blood pressure regulation, arterial stiffness, endothelial integrity, lipid metabolism, and mitochondrial energy production in cardiac tissue. Where the evidence is strong, I say so. Where it is contested or preliminary, I say that too.
The nutrients covered here — including aged garlic extract, ubiquinol, vitamin K2 MK-7, magnesium, omega-3 DHA, and olive leaf extract — each have a plausible mechanistic rationale and, in most cases, at least one well-conducted randomised controlled trial behind them. None are substitutes for antihypertensive medication, statins, or lifestyle intervention. All are components of KōJō Daily Formula v4.1, dosed at levels consistent with the clinical literature.
What follows is a structured, citation-grounded account of where the science stands in 2025.
Blood Pressure: The Magnesium and Garlic Evidence Base
Blood pressure is the single most modifiable cardiovascular risk factor in the general population. The relationship between dietary mineral intake and arterial tone has been studied for decades, with magnesium occupying a particularly well-examined position in that literature.
Magnesium influences vascular smooth muscle relaxation via its role as a physiological calcium antagonist. When intracellular magnesium is adequate, smooth muscle cells maintain appropriate tone; when it is depleted, vasoconstriction increases. The epidemiological signal is reasonably consistent: lower serum magnesium correlates with higher blood pressure in observational cohorts. A 2022 review synthesising both dietary intake data and serum measurements concluded that the relationship is biologically plausible and supported across multiple study designs, though effect sizes vary considerably depending on baseline magnesium status and measurement method. Banjanin 2022
A more recent 2025 systematic review and meta-analysis specifically examining circulating magnesium levels and hypertension found no consistent direction across all included studies — a finding that should temper enthusiasm for magnesium as a standalone antihypertensive intervention. Tirani 2025 What that heterogeneity more likely reflects is that magnesium supplementation produces the clearest benefit in individuals who are actually deficient, which is not a trivial population: dietary surveys consistently show that a significant proportion of UK adults fall below recommended intake. A 2021 review focused specifically on older populations found that magnesium deficiency in this group is associated with hypertension and that correction of deficiency is associated with blood pressure improvements. Dominguez 2021
Aged garlic extract (AGE) presents a different mechanism. The aging process converts allicin and related organosulphur compounds into more stable, less odorous derivatives — S-allylcysteine and S-allylmercaptocysteine — that appear to influence nitric oxide bioavailability and endothelial function. A 2024 systematic review and meta-analysis of randomised controlled trials in hypertensive patients found that AGE supplementation was associated with reductions in both systolic and diastolic blood pressure, though the authors noted heterogeneity across trials. Saadh 2024 A 2023 triple-blind RCT in subjects with Grade I hypertension already on antihypertensive drug therapy found that an optimised AGE preparation was associated with additional systolic blood pressure reductions over the trial period. Serrano 2023
KōJō Daily Formula contains Magnesium Bisglycinate at 1000mg (200mg elemental) and Aged Garlic Extract at 600mg — the latter consistent with doses used in the RCT literature.
Arterial Calcification and Vitamin K2 MK-7
Arterial stiffness and calcification represent a distinct cardiovascular risk pathway, separate from — though interacting with — blood pressure. The calcification of arterial walls and cardiac valves is not simply an inevitable consequence of ageing; it is an actively regulated process in which vitamin K-dependent proteins play a central inhibitory role.
Matrix Gla Protein (MGP) is the most potent known inhibitor of arterial calcification. It requires carboxylation by vitamin K to become active. In a state of vitamin K insufficiency, MGP remains undercarboxylated and functionally inactive, allowing calcium to deposit in arterial tissue. This mechanism is well-established at the molecular level. Jadhav 2024
Vitamin K2 in the MK-7 form has superior bioavailability compared to K1 and a substantially longer half-life, which means it more effectively reaches peripheral tissues including arterial walls. This pharmacokinetic advantage makes MK-7 the preferred form for cardiovascular applications. Jadhav 2024
The clinical trial data is more nuanced. A randomised double-blind trial published in Circulation in 2022 examined whether combined vitamin K2 (MK-7) and vitamin D supplementation could slow the progression of aortic valve calcification in patients with established aortic stenosis. The results did not demonstrate a statistically significant reduction in calcification progression in the overall cohort, though the authors noted that the intervention may have been introduced too late in the disease course for structural reversal to be feasible. Diederichsen 2022 This is an important distinction: the mechanistic rationale supports K2 as a preventive measure in individuals without established calcification, not as a treatment for advanced valvular disease.
A separate line of evidence concerns endothelial function. Animal research demonstrated that MK-7 treatment improved nitric oxide-dependent endothelial vasodilation in a mouse model of atherosclerosis, suggesting vascular benefits beyond calcification inhibition alone. Bar 2020
KōJō Daily Formula contains Vitamin K2 MK-7 at 180mcg, alongside Vitamin D3 at 50mcg — a pairing consistent with the trial literature and with EFSA's NHC register, which approves the wording "Vitamin K contributes to normal blood clotting."
Mitochondrial Function and Cardiac Energy: The CoQ10 Question
The heart is the most metabolically demanding organ in the body, contracting roughly 100,000 times per day. Its energy requirements are met almost entirely by mitochondrial oxidative phosphorylation, a process in which Coenzyme Q10 (CoQ10) is an indispensable electron carrier in the respiratory chain.
Endogenous CoQ10 synthesis declines with age and is further suppressed by statin therapy — a pharmacological irony given that statins are prescribed to reduce cardiovascular risk. The question of whether supplemental CoQ10 meaningfully compensates for this decline, and whether it translates into clinically relevant cardiovascular outcomes, has been debated for decades.
A 2024 review comparing ubiquinone (the oxidised form) and ubiquinol (the reduced, active form) concluded that recent evidence supports the beneficial effect of CoQ10 supplementation in the treatment and prevention of cardiovascular disease, particularly in patients with heart failure. The review noted that ubiquinol may have advantages in bioavailability, particularly in older individuals and those with more severe disease states. Fladerer 2024
A 2021 comprehensive review of CoQ10 supplementation efficacy confirmed the cardiovascular signal while also identifying the formulation challenge: CoQ10 is a lipophilic molecule with poor aqueous solubility, meaning bioavailability varies substantially between products depending on particle size, delivery matrix, and co-administration with dietary fat. Arenas-Jal 2021 This is not a trivial concern for anyone evaluating supplement products; a low-bioavailability CoQ10 preparation may deliver negligible plasma elevation regardless of the label dose.
It is worth noting that CoQ10's role extends beyond the cardiovascular system — it functions as the only endogenous lipid-soluble antioxidant synthesised within cells, protecting mitochondrial membranes from oxidative damage. Rauchová 2022 In cardiac tissue, where oxidative stress is particularly high, this antioxidant function may be as relevant as the bioenergetic one.
KōJō Daily Formula contains Ubiquinol at 100mg — the reduced, active form, chosen specifically for its superior bioavailability profile relative to standard ubiquinone.
Omega-3 Fatty Acids: Navigating a Contested Literature
Few areas of cardiovascular nutrition research have generated more controversy in the past decade than omega-3 fatty acids. The initial epidemiological observations — that populations consuming high quantities of marine-derived omega-3s had lower rates of cardiovascular mortality — generated enormous enthusiasm. The subsequent clinical trial record has been considerably more complicated.
EPA and DHA lower triglyceride levels reliably; this is not disputed. The mechanism involves reduced hepatic triglyceride synthesis and increased fatty acid oxidation. What remains contested is whether triglyceride reduction translates into reduced cardiovascular events at the doses achievable through supplementation. Mason 2023
The trial landscape is characterised by inconsistency. High-dose EPA-only preparations (specifically icosapent ethyl at 4g/day) demonstrated significant cardiovascular event reduction in the REDUCE-IT trial. Trials using EPA+DHA combinations at lower doses have generally shown more modest or null results. A 2023 review concluded that the outcome differences are likely attributable to variations in dosage, formulation, and the EPA:DHA ratio, rather than omega-3s being uniformly effective or ineffective. Sherratt 2023
A 2021 update on omega-3 polyunsaturated fatty acids and cardiovascular health concluded that the evidence supports a modest cardiovascular benefit, particularly for triglyceride reduction and possibly for secondary prevention in high-risk populations, while acknowledging that the evidence for primary prevention in the general population is less compelling. Elagizi 2021
KōJō Daily Formula contains Algal DHA at 250mg. This is a plant-derived, sustainable source of DHA — relevant for individuals who do not consume oily fish regularly. At 250mg, this dose is positioned as a dietary contribution to DHA intake rather than a pharmacological triglyceride-lowering intervention. The evidence for DHA specifically in supporting normal brain function is well-established via EFSA's NHC register, which approves the wording "DHA contributes to the maintenance of normal brain function" and "DHA contributes to the maintenance of normal blood triglyceride levels" at 2g/day. The 250mg dose in KōJō contributes meaningfully to daily intake, particularly for those with low dietary DHA.
Endothelial Health: Olive Leaf Extract and Grape Seed Extract
The endothelium — the single-cell layer lining every blood vessel in the body — is not merely a passive barrier. It is an active endocrine tissue producing nitric oxide, regulating vascular tone, modulating inflammation, and controlling platelet adhesion. Endothelial dysfunction, characterised by reduced nitric oxide bioavailability and increased inflammatory signalling, is considered an early and central event in atherosclerosis.
Olive leaf extract (OLE) has attracted research interest for its polyphenolic content, particularly oleuropein and its derivatives. These compounds appear to influence endothelial function through multiple pathways: antioxidant activity that preserves nitric oxide from oxidative degradation, and direct anti-inflammatory effects on endothelial cells. A 2023 study examining the effects of OLE bioactive compounds — specifically oleacin and oleuropein-aglycone — on senescent endothelial cells found significant anti-inflammatory effects, with reductions in key inflammatory markers in aged endothelial tissue. Silvestrini 2023
Animal research has extended this to in vivo blood pressure and vascular function outcomes. A 2021 study in aged Wistar rats found that OLE supplementation improved vascular and metabolic alterations associated with ageing, including improvements in endothelial-dependent vasodilation. González-Hedström 2021 A further 2021 study demonstrated that adding OLE to an omega-3-rich oil mixture attenuated age-induced hypertension and insulin resistance in rats, with the OLE appearing to stabilise the omega-3 fatty acids against oxidation — a potentially relevant interaction for combination supplement formulations. González-Hedström 2021
The human RCT evidence for OLE specifically in cardiovascular endpoints remains more limited than the animal and mechanistic literature. The honest position is that the mechanistic rationale is strong and the preclinical data is encouraging, but large-scale human cardiovascular outcome trials are lacking.
Grape seed extract, rich in oligomeric proanthocyanidins (OPCs), operates via similar antioxidant and nitric oxide-preserving mechanisms. The evidence base for grape seed extract in blood pressure and endothelial function is modest but directionally consistent across small trials.
KōJō Daily Formula contains Olive Leaf Extract at 500mg and Grape Seed Extract at 200mg.
Lipid Metabolism: The Garlic-Cholesterol Signal
Beyond blood pressure, the organosulphur compounds in aged garlic extract have been investigated for effects on lipid profiles. The proposed mechanisms include modulation of HMG-CoA reductase activity, reduced cholesterol absorption, and antioxidant protection of LDL particles against oxidative modification.
A 2024 randomised controlled trial examined a dietary supplement containing onion and garlic extract in healthy volunteers with mild hypercholesterolaemia. The study found LDL-cholesterol reductions in the treatment group, with the authors noting that the combination of allium-derived compounds appeared to produce a meaningful effect in individuals with borderline elevated cholesterol who are typically not candidates for pharmaceutical intervention. Vezza 2024
The effect sizes observed in garlic and cholesterol trials are modest relative to pharmaceutical lipid-lowering agents. This is not a criticism — it is context. For individuals with mildly elevated LDL who are not indicated for statin therapy, a modest reduction in LDL alongside blood pressure support from the same ingredient represents a meaningful contribution to overall cardiovascular risk management, particularly when considered as part of a broader dietary and lifestyle approach.
It is also worth noting that oxidised LDL, rather than total LDL per se, is increasingly understood as the more atherogenic species. Antioxidant compounds that reduce LDL oxidation — including those found in aged garlic extract, olive leaf extract, and grape seed extract — may therefore contribute to cardiovascular risk reduction through mechanisms not captured by standard lipid panels.
Pine Bark Extract and the Nitric Oxide Pathway
Pine bark extract (standardised to procyanidin content, commonly sold as Pycnogenol) has a reasonably well-developed evidence base for endothelial function, centred on its capacity to support nitric oxide synthesis in endothelial cells. Nitric oxide is the primary vasodilatory signal produced by the endothelium; its reduced bioavailability is a hallmark of endothelial dysfunction and a precursor to hypertension and atherosclerosis.
The procyanidins in pine bark extract appear to stimulate endothelial nitric oxide synthase (eNOS) activity, the enzyme responsible for producing nitric oxide from L-arginine. They also reduce oxidative degradation of nitric oxide by scavenging superoxide radicals. The net effect is improved nitric oxide availability and, in clinical studies, improvements in endothelial-dependent vasodilation and modest reductions in blood pressure.
The evidence base for pine bark extract is largely composed of smaller trials rather than large-scale cardiovascular outcome studies, which limits the strength of conclusions that can be drawn. The mechanistic rationale is, however, well-grounded, and the safety profile is favourable.
KōJō Daily Formula contains Pine Bark Extract at 150mg.
What KōJō Daily Formula Does for Cardiovascular Health
KōJō Daily Formula v4.1 addresses cardiovascular function through several distinct but interacting mechanisms: blood pressure regulation, arterial calcification inhibition, mitochondrial energy production in cardiac tissue, endothelial integrity, and lipid metabolism. The following ingredients are directly relevant to this cluster, at their exact formulated doses:
| Ingredient | Dose | Primary Cardiovascular Mechanism | |---|---|---| | Aged Garlic Extract | 600mg | Blood pressure reduction; modest LDL-cholesterol lowering; antioxidant protection of LDL | | Magnesium Bisglycinate | 1000mg (200mg elemental) | Vascular smooth muscle relaxation; calcium antagonism; blood pressure support | | Vitamin K2 MK-7 | 180mcg | Activation of Matrix Gla Protein; inhibition of arterial calcification | | Vitamin D3 | 50mcg | Paired with K2 for calcification regulation; EFSA-approved for normal muscle function | | Ubiquinol | 100mg | Mitochondrial electron transport in cardiac tissue; lipid-soluble antioxidant protection | | Algal DHA | 250mg | Triglyceride metabolism; dietary DHA contribution for non-fish consumers | | Olive Leaf Extract | 500mg | Anti-inflammatory effects on endothelial cells; antihypertensive in preclinical models | | Grape Seed Extract | 200mg | OPC-mediated antioxidant support; LDL oxidation protection | | Pine Bark Extract | 150mg | eNOS stimulation; nitric oxide bioavailability; endothelial vasodilation | | Vitamin C | 500mg | Endothelial antioxidant support; EFSA-approved for normal collagen synthesis in blood vessels |
A note on mechanism stacking
These ingredients do not operate in isolation. Olive leaf extract's antioxidant activity may stabilise DHA against oxidation — a synergy observed in animal research. González-Hedström 2021 Vitamin K2 and D3 work in concert on calcification pathways. Diederichsen 2022 Ubiquinol's antioxidant function complements the nitric oxide-preserving effects of pine bark and grape seed extract at the endothelial level. Rauchová 2022
This is not a claim that the combination produces effects greater than the sum of its parts — the evidence for specific synergies in humans is limited. It is an observation that the mechanisms are complementary rather than redundant, and that a formulation addressing multiple cardiovascular pathways simultaneously is a more coherent approach than single-ingredient supplementation for a multifactorial condition.
What this is not
KōJō Daily Formula is not a cardiovascular medication. It does not replace antihypertensive drugs, statins, anticoagulants, or any other prescribed cardiovascular therapy. Individuals with diagnosed cardiovascular disease, those on anticoagulant therapy (vitamin K2 is relevant here — consult your prescriber), or those with significant lipid abnormalities should discuss any supplementation with their GP or cardiologist before starting.
The evidence reviewed here supports a role for these ingredients in the maintenance of normal cardiovascular function in adults without established disease — a preventive rather than therapeutic position, consistent with the regulatory framework governing food supplements in the UK.
All clinical claims in this article are supported by citations from peer-reviewed literature. KōJō Daily Formula v4.1 doses are exact. This article does not constitute medical advice.
Frequently Asked Questions
The article mentions magnesium helps blood pressure, but the 2025 meta-analysis found no consistent direction. Should I actually take it?
Magnesium works best if you're actually deficient, which is common in UK adults. If your intake is already adequate, supplementation won't reliably lower blood pressure. A dietary assessment first makes sense before supplementing.
Why is ubiquinol in KōJō instead of regular CoQ10, and does it actually make a difference?
Ubiquinol is the active, reduced form with better bioavailability, especially in older people. Standard ubiquinone is poorly absorbed. Since CoQ10 is fat-soluble and formulation quality determines whether it reaches therapeutic levels, the form matters considerably.
The vitamin K2 section says it's preventive, not therapeutic. Does that mean it's pointless if I already have arterial stiffness?
K2 MK-7 activates the protein that stops calcium depositing in arteries. The evidence suggests it works best before calcification develops. Once established, structural reversal isn't feasible. It's a prevention tool, not a reversal tool.
You mention aged garlic extract worked in RCTs, but how much is actually in KōJō and is that the dose from the trials?
KōJō contains 600mg aged garlic extract, which matches the doses used in the RCT literature, including the 2023 triple-blind trial showing additional blood pressure reductions alongside medication.
The omega-3 section cuts off mid-sentence. What's the actual evidence for taking fish oil supplements?
Omega-3s reliably lower triglycerides. Whether that translates to fewer cardiovascular events depends heavily on dose, formulation, and EPA:DHA ratio. High-dose EPA-only showed benefit in REDUCE-IT; lower-dose combinations show modest or null results. The evidence is genuinely mixed.
